Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (401-410 of 497) with videos related to

Pageof 50
Sort By:
Circulation|June 9, 1999
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experienceM W McClure, S D Berkowitz, R Sparapani, et al.
Stroke|April 26, 2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialKa Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, et al.
Endoscopy|July 30, 2010
Evidence-based recommendations for bowel cleansing before colonoscopy in children: a report from a national working groupD Turner, A Levine, B Weiss, et al.
Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.
Heart (British Cardiac Society)|May 22, 2021
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery diseaseGilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 50

Showing results (401-410 of 497) with videos related to

Sort By:
Pageof 50
Circulation|June 9, 1999
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experienceM W McClure, S D Berkowitz, R Sparapani, et al.
Stroke|April 26, 2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialKa Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, et al.
Endoscopy|July 30, 2010
Evidence-based recommendations for bowel cleansing before colonoscopy in children: a report from a national working groupD Turner, A Levine, B Weiss, et al.
Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.
Heart (British Cardiac Society)|May 22, 2021
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery diseaseGilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 50